Matt Hewitt
Stock Analyst at Craig-Hallum
(3.21)
# 1,129
Out of 4,667 analysts
43
Total ratings
40.62%
Success rate
5.61%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $25.01 | +27.95% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $41.82 | +53.04% | 6 | Oct 31, 2024 | |
| CSBR Champions Oncology | Upgrades: Buy | $6 | $4.32 | +38.89% | 2 | Sep 12, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $111.56 | +25.49% | 3 | Jul 9, 2024 | |
| SLP Simulations Plus | Reiterates: Buy | $56 | $27.58 | +103.05% | 7 | Jul 3, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $3.21 | +211.53% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $19.17 | +56.49% | 3 | May 2, 2024 | |
| CDMO Avid Bioservices | Maintains: Buy | $22 → $16 | $12.22 | +30.93% | 4 | Dec 8, 2023 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $3.49 | +100.57% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $138.90 | +43.99% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.90 | +156.41% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $9.00 | +233.33% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $4.61 | +8,576.79% | 1 | Jan 4, 2022 |
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $25.01
Upside: +27.95%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $41.82
Upside: +53.04%
Champions Oncology
Sep 12, 2024
Upgrades: Buy
Price Target: $6
Current: $4.32
Upside: +38.89%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $111.56
Upside: +25.49%
Simulations Plus
Jul 3, 2024
Reiterates: Buy
Price Target: $56
Current: $27.58
Upside: +103.05%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $3.21
Upside: +211.53%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $19.17
Upside: +56.49%
Avid Bioservices
Dec 8, 2023
Maintains: Buy
Price Target: $22 → $16
Current: $12.22
Upside: +30.93%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $3.49
Upside: +100.57%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $138.90
Upside: +43.99%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $3.90
Upside: +156.41%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $9.00
Upside: +233.33%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $4.61
Upside: +8,576.79%